A machine learning model of response to hypomethylating agents in myelodysplastic syndromes

被引：9

作者：

Radakovich, Nathan ^{[1
,2
]}

Sallman, David A. ^{[3
]}

Buckstein, Rena ^{[4
]}

Brunner, Andrew ^{[5
]}

Dezern, Amy ^{[6
]}

Mukerjee, Sudipto ^{[7
]}

Komrokji, Rami ^{[3
]}

Al-Ali, Najla ^{[3
]}

Shreve, Jacob ^{[8
]}

Rouphail, Yazan ^{[9
]}

Parmentier, Anne ^{[4
]}

Mamedov, Alexandre ^{[4
]}

Siddiqui, Mohammed ^{[4
]}

Guan, Yihong ^{[10
]}

Kuzmanovic, Teodora ^{[10
]}

Hasipek, Metis ^{[10
]}

Jha, Babal ^{[10
]}

Maciejewski, Jaroslaw P. ^{[10
]}

Sekeres, Mikkael A. ^{[11
]}

Nazha, Aziz ^{[12
]}

机构：

[1] Cleveland Clin, Leukemia Program, Dept Hematol & Med Oncol, Taussig Canc Inst, Cleveland, OH 44106 USA

[2] Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA

[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

[4] Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada

[5] Massachusetts Gen Hosp, Boston, MA 02114 USA

[6] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[7] Cleveland Clin, Dept Hematol & Med Oncol, Taussig Canc Inst, Cleveland, OH 44106 USA

[8] Cleveland Clin, Dept Internal Med, Cleveland, OH 44106 USA

[9] Ohio State Univ, Columbus, OH 43210 USA

[10] Cleveland Clin, Dept Translat Hematol & Oncol Res, Taussig Canc Inst, Cleveland, OH 44106 USA

[11] Univ Miami, Div Hematol, Sylvester Comprehens Canc Ctr, Miami, FL USA

[12] Thomas Jefferson Univ, Dept Oncol, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA

来源：

ISCIENCE | 2022年 / 25卷 / 10期

关键词：

ADAPTED THERAPY; MDS;

D O I：

10.1016/j.isci.2022.104931

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Hypomethylating agents (HMA) prolong survival and improve cytopenias in indi-viduals with higher-risk myelodysplastic syndrome (MDS). Only 30-40% of pa-tients, however, respond to HMAs, and responses may not occur for more than 6 months after HMA initiation. We developed a model to more rapidly assess HMA response by analyzing early changes in patients' blood counts. Three insti-tutions' data were used to develop a model that assessed patients' response to therapy 90 days after the initiation using serial blood counts. The model was developed with a training cohort of 424 patients from 2 institutions and validated on an independent cohort of 90 patients. The final model achieved an area under the receiver operating characteristic curve (AUROC) of 0.79 in the train/test group and 0.84 in the validation group. The model provides cohort-wide and in-dividual-level explanations for model predictions, and model certainty can be interrogated to gauge the reliability of a given prediction.

引用

页数：12

共 18 条

[1] PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study [J].

Barrington, Sally F. ;

Kirkwood, Amy A. ;

Franceschetto, Antonella ;

Fulham, Michael J. ;

Roberts, Thomas H. ;

Almquist, Helen ;

Brun, Eva ;

Hjorthaug, Karin ;

Viney, Zaid N. ;

Pike, Lucy C. ;

Federico, Massimo ;

Luminari, Stefano ;

Radford, John ;

Trotman, Judith ;

Fossa, Alexander ;

Berkahn, Leanne ;

Molin, Daniel ;

D'Amore, Francesco ;

Sinclair, Donald A. ;

Smith, Paul ;

O'Doherty, Michael J. ;

Stevens, Lindsey ;

Johnson, Peter W. .

BLOOD, 2016, 127 (12) :1531-1538

[2] Response-adapted therapy in Hodgkin lymphoma [J].

Broadfoot, Jack ;

Johnson, Peter W. M. .

HEMATOLOGICAL ONCOLOGY, 2017, 35 :33-36

[3] Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia [J].

Cheson, Bruce D. ;

Greenberg, Peter L. ;

Bennett, John M. ;

Lowenberg, Bob ;

Wijermans, Pierre W. ;

Nimer, Stephen D. ;

Pinto, Antonio ;

Beran, Miloslav ;

de Witte, Theo M. ;

Stone, Richard M. ;

Mittelman, Moshe ;

Sanz, Guillermo F. ;

Gore, Steven D. ;

Schiffer, Charles A. ;

Kantarjian, Hagop .

BLOOD, 2006, 108 (02) :419-425

[4] Prospects for Venetoclax in Myelodysplastic Syndromes [J].

Garcia, Jacqueline S. .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2020, 34 (02) :441-+

[5] Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study [J].

Garcia-Manero, Guillermo ;

Griffiths, Elizabeth A. ;

Steensma, David P. ;

Roboz, Gail J. ;

Wells, Richard ;

McCloskey, James, II ;

Odenike, Olatoyosi ;

DeZern, Amy E. ;

Yee, Karen ;

Busque, Lambert ;

O'Connell, Casey ;

Michaelis, Laura C. ;

Brandwein, Joseph ;

Kantarjian, Hagop ;

Oganesian, Aram ;

Azab, Mohammad ;

Savona, Michael R. .

BLOOD, 2020, 136 (06) :674-683

[6] Revised International Prognostic Scoring System for Myelodysplastic Syndromes [J].

Greenberg, Peter L. ;

Tuechler, Heinz ;

Schanz, Julie ;

Sanz, Guillermo ;

Garcia-Manero, Guillermo ;

Sole, Francesc ;

Bennett, John M. ;

Bowen, David ;

Fenaux, Pierre ;

Dreyfus, Francois ;

Kantarjian, Hagop ;

Kuendgen, Andrea ;

Levis, Alessandro ;

Malcovati, Luca ;

Cazzola, Mario ;

Cermak, Jaroslav ;

Fonatsch, Christa ;

Le Beau, Michelle M. ;

Slovak, Marilyn L. ;

Krieger, Otto ;

Luebbert, Michael ;

Maciejewski, Jaroslaw ;

Magalhaes, Silvia M. M. ;

Miyazaki, Yasushi ;

Pfeilstoecker, Michael ;

Sekeres, Mikkael ;

Sperr, Wolfgang R. ;

Stauder, Reinhard ;

Tauro, Sudhir ;

Valent, Peter ;

Vallespi, Teresa ;

van de Loosdrecht, Arjan A. ;

Germing, Ulrich ;

Haase, Detlef .

BLOOD, 2012, 120 (12) :2454-2465

[7]

Huang J., 2018, BMC CANCER, V18

[8] Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes [J].

Itzykson, Raphael ;

Crouch, Simon ;

Travaglino, Erica ;

Smith, Alex ;

Symeonidis, Argiris ;

Hellstrom-Lindberg, Eva ;

Sanz, Guillermo ;

Cermak, Jaroslav ;

Stauder, Reinhard ;

Elena, Chiara ;

Germing, Ulrich ;

Mittelman, Moshe ;

Langemeijer, Saskia ;

Madry, Krzysztof ;

Tatic, Aurelia ;

Holm, Mette Skov ;

Almeida, Antonio Medina ;

Savic, Aleksander ;

Simec, Njetocka Gredelj ;

Luno, Elise ;

Culligan, Dominic ;

Guerci-Bresler, Agnes ;

Malcovati, Luca ;

van Marrewijk, Corine ;

Bowen, David ;

de Witte, Theo ;

Fenaux, Pierre .

BLOOD ADVANCES, 2018, 2 (16) :2079-2089

[9] Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial [J].

Jackson, Graham H. ;

Davies, Faith E. ;

Pawlyn, Charlotte ;

Cairns, David A. ;

Striha, Alina ;

Collett, Corinne ;

Waterhouse, Anna ;

Jones, John R. ;

Kishore, Bhuvan ;

Garg, Mamta ;

Williams, Cathy D. ;

Karunanithi, Kamaraj ;

Lindsay, Jindriska ;

Wilson, Jamie N. ;

Jenner, Matthew W. ;

Cook, Gordon ;

Kaiser, Martin F. ;

Drayson, Mark T. ;

Owen, Roger G. ;

Russell, Nigel H. ;

Gregory, Walter M. ;

Morgan, Gareth J. .

LANCET HAEMATOLOGY, 2019, 6 (12) :E616-E629

[10] What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)? [J].

Komrokji, Rami ;

Al Ali, Najla ;

Padron, Eric ;

Lancet, Jeffrey ;

Nazha, Aziz ;

Steensma, David ;

DeZern, Amy ;

Roboz, Gail ;

Garcia-Manero, Guillermo ;

Sekeres, Mikkael A. ;

Sallman, David .

LEUKEMIA & LYMPHOMA, 2021, 62 (11) :2762-2767

← 1 2 →